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ABSTRACT: Piperine activates TRPV1 (transient receptor
potential vanilloid type 1 receptor) receptors and modulates γ-
aminobutyric acid type A receptors (GABAAR). We have
synthesized a library of 76 piperine analogues and analyzed
their eﬀects on GABAAR by means of a two-microelectrode
voltage-clamp technique. GABAAR were expressed in Xenopus
laevis oocytes. Structure−activity relationships (SARs) were
established to identify structural elements essential for
eﬃciency and potency. Eﬃciency of piperine derivatives was
signiﬁcantly increased by exchanging the piperidine moiety
with either N,N-dipropyl, N,N-diisopropyl, N,N-dibutyl, p-
methylpiperidine, or N,N-bis(triﬂuoroethyl) groups. Potency
was enhanced by replacing the piperidine moiety by N,N-
dibutyl, N,N-diisobutyl, or N,N-bistriﬂuoroethyl groups. Linker modiﬁcations did not substantially enhance the eﬀect on
GABAAR. Compound 23 [(2E,4E)-5-(1,3-benzodioxol-5-yl)-N,N-dipropyl-2,4-pentadienamide] induced the strongest
modulation of GABAA (maximal GABA-induced chloride current modulation (IGABA‑max = 1673% ± 146%, EC50 = 51.7 ± 9.5
μM), while 25 [(2E,4E)-5-(1,3-benzodioxol-5-yl)-N,N-dibutyl-2,4-pentadienamide] displayed the highest potency (EC50 = 13.8
± 1.8 μM, IGABA‑max = 760% ± 47%). Compound 23 induced signiﬁcantly stronger anxiolysis in mice than piperine and thus may
serve as a starting point for developing novel GABAAR modulators.
■ INTRODUCTION
γ-Aminobutyric acid type A (GABAA) receptors are the major
inhibitory neurotransmitter receptors in mammalian brain.1−3
GABAA receptors belong to the superfamily of Cys loop ligand-
gated ion channels. Five receptor subunits form a central
chloride-conducting pore.4−6 Nineteen genes encoding diﬀer-
ent subunits have been discovered in the human genome,
comprising α1−6, β1−3, γ1−3, δ, ε, θ, π, and ρ1−3.
7,8 Diﬀerent
subunit combinations may theoretically form a vast number of
receptor subtypes with diﬀerent pharmacological properties
(see ref 9 for review). There is consensus that the most
abundantly occurring receptor subtype is formed of two α1, two
β2, and one γ2 subunits (α1β2γ2 receptor).
10−12
Drugs that enhance chloride currents through GABAA
receptors play an important role in the treatment of general
anxiety, panic disorders, sleep disturbances, and epilepsy.13−17
The most widely used benzodiazepines induce, however, a
variety of side eﬀects including dependence, unwanted
sedation, and amnesia, complicating their long-term use.18−20
Hence, there is high unmet medical need for GABAA receptor
modulators lacking these unwanted eﬀects.
Besides their modulation by clinically used drugs such as
benzodiazepines, barbiturates, neurosteroids, and anes-
thetics,3,9,15,21−27 GABAA receptors are modulated by numer-
ous natural products that may provide lead structures for drug
development.28−30
In this context, we31 and others32 have reported that piperine
(1-piperoylpiperidine), the pungent component of several
pepper species and activator of transient receptor potential
vanilloid type 1 receptor (TRPV1),33 also modulates GABAA
receptors. We could establish that replacing the piperidine ring
of piperine by a N,N-diisobutyl residue, resulting in (2E,4E)-5-
(1,3-benzodioxol-5-yl))-N,N-diisobutyl-2,4-pentadienamide
(SCT-66;34 referred to as 24 in this work), diminishes the
interaction with TRPV1 receptors. Furthermore, 24 enhanced
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chloride currents through GABAA receptors more potently and
more eﬃciently than piperine and displayed, concordantly, a
stronger anxiolytic action.34
Based on these ﬁndings, a library of piperine derivatives was
synthesized and investigated with respect to modulation of
α1β2γ2S GABAA receptors expressed in Xenopus laevis oocytes.
Within this study we emphasized modiﬁcations at the amide
functionality and on the diene motif within piperine in order to
enhance the modulatory potential of analogue structures. Their
structure−activity relationship on GABAA receptors was
analyzed by establishing binary classiﬁcation models.
■ RESULTS AND DISCUSSION
Modiﬁcation of Amide Nitrogen. Starting with piperine
as lead structure from prior biological assessment, the molecule
can be structurally divided into three parts: the 1,3-
benzodioxole or aromatic function, the oleﬁnic linker region
comprising four carbon atoms, and the amide function natively
constituted by a piperidine ring (Figure 1). Within this study,
we investigated modiﬁcations at the amide group as well as in
the linker region.
Modiﬁcations at the amide function were implemented in a
straightforward fashion (Scheme 1). Piperic acid amides (1−16,
20−23, and 25−43) were synthesized by treating piperic acid
chloride with the corresponding amine in the presence of
triethylamine in tetrahydrofuran (THF). Compounds 17 and
18 were prepared in the same way from benzodioxolyl acryloyl
chloride. Treatment of piperine with Lawesson’s reagent35 gave
thioamide 44. Reduction of the carbonyl group of piperine with
lithium aluminum hydride aﬀorded unsaturated amine 45
(Scheme 2).
First, we studied the eﬀects of systematic modiﬁcations of the
amide nitrogen on IGABA modulation through α1β2γ2S receptors.
As illustrated in Figure 2A,B, 10 compounds (22, 23, 25, 28,
33, 34, 35, 38, and 43) at 100 μM induced stronger IGABA
modulation than piperine (≥220%)31 and were classiﬁed as
highly active. IGABA potentiation of these compounds ranged
between 294% ± 66% (28) and 1091% ± 257% (23, see Table
1). At this concentration, three derivatives (17, 30, and 39)
were less eﬃcient, while the other compounds did not
signiﬁcantly modulate IGABA (see Figure 2A,B and Table 1).
Five derivatives of this ﬁrst set (22, 23, 25, 35, and 43) with
amide modiﬁcations enhanced IGABA through α1β2γ2S GABAA
receptors with higher eﬃciency (IGABA‑max: 23 > 22 > 25 > 35)
and/or higher potency (EC50: 25 < 43) than piperine (Figure
2C,D and Table 2).
N,N-Dipropyl-Substituted Compounds 22 And 23
Display the Highest Eﬃciency. Compounds 22 (N,N-
dipropyl) and 23 (N,N-diisopropyl) modulated IGABA most
eﬃciently (IGABA‑max for 22, 1581% ± 74%; IGABA‑max for 23,
1673% ± 146%; IGABA‑max for piperine, 302% ± 27%).
Compounds 35 (IGABA‑max 733% ± 60%) and 25 (IGABA‑max
760% ± 47%) were less eﬃcient, underscoring the important
role of a noncyclic disubstituted amide motif (Figure 2C).
N,N-Dibutyl-Substituted Compound 25 Displays the
Highest Potency. Figure 2D illustrates IGABA modulation by
the most potent N-substituted piperine derivative (EC50 for 25,
13.8 ± 1.8 μM < EC50 for 43, 23.1 ± 3.3 μM < EC50 for
piperine, 52.4 ± 9.4 μM31). Based on the modiﬁcations at the
amide group, it can be concluded that installation of noncyclic
substituents bearing 3−4 carbons each at the tertiary amide
improves both eﬃcacy and potency of the analogue
compounds.
Rigidiﬁcation of the Linker Region Has No Signiﬁcant
Eﬀect on IGABA Modulation. The inﬂuence of linker rigidity
on IGABA modulation was studied by means of a library
comprising 32 linker derivatives. According to Zaugg et al.31
and Pedersen et al.,32 a carbon chain containing at least four
carbons, a conjugated double bond adjacent to the amide
group, and a bulky amine moiety seem to facilitate eﬃcient
receptor binding and/or IGABA modulation.
Based on previous reports by Zaugg et al.,31 we hypothesized
that rigidiﬁcation of the linker part of the structure may
beneﬁcially aﬀect biological activity.31 This assessment was
based in particular on a decrease in modulatory capacity when
partially saturated linkers were installed or when structural
ﬂexibility was increased by extending the linker length.
Three major structural modiﬁcations were envisaged
(Scheme 1). (i) Replacement of the linker by an aryl ring
(phenyl, heteroaryl, naphthyl): in this arrangement, both alkene
groups of the diene system of the linker would be integrated
into the rigid aromatic core. (ii) Integration of one linker
double bond into a naphthyl ring: this compound class was
expected to render more ﬂexibility but still adopt a more
rigidiﬁed system compared to the piperine diene structure;
moreover, arrangement should allow for diﬀerent angles of the
aryl core relative to the amide anchoring group depending on
the substitution site at the naphthyl system. (iii) “Ring closure”
of the diene motif with the aryl part, consequently generating a
carboxylate-substituted naphthyl lead structure: in this arrange-
ment the double bond adopts a bent geometry, and again
diﬀerent angles of the aryl and amide parts can be obtained
depending on the substitution site.
For the synthesis of aryl-bridged compounds, two diﬀerent
methods were utilized. For a number of products (46, 49, 53,
and 58−64) (Scheme 3), the corresponding bromo-substituted
aromatic carboxylic acids were reacted with 3,4-
(methylenedioxy)phenylboronic acid under Suzuki−Miyaura
cross-coupling conditions.36 The resulting bis(aryl)carboxylic
acids were converted to the ﬁnal amide products via the
corresponding acid chloride intermediates. Alternatively, the
corresponding bromobenzoic acid amides were prepared prior
to the coupling step. Subsequent Suzuki−Miyaura coupling
with 3,4-(methylenedioxy)phenylboronic acid aﬀorded the ﬁnal
products 47, 48, 50−52, and 54−57 (Scheme 3).
In order to access the 5-position of the naphtho[2,3-
d]dioxole core, naphtho[2,3-d]dioxol-5-ol triﬂate was chosen as
a precursor.37 Heck coupling38 employing methyl acrylate
aﬀorded 65a, which gave acrylic acid 65b after cleavage of the
methyl ester (Scheme 4). Amide formation yielded the ﬁnal
products 65−67.
Iridium-catalyzed direct borylation39 of naphtho[2,3-d]-
dioxole allowed direct access to the 6-position of the
naphtho[2,3-d]dioxole core. Boronic acid ester 68a obtained
in this step was converted into the corresponding bromide40
Figure 1. Piperine molecule can be structurally divided into three
moieties: the 1,3-benzodioxole or aromatic function, the linker region
comprising four carbon atoms, and the amide function natively
constituted by a piperidine ring.
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68b and coupled under standard Heck cross-coupling
conditions to aﬀord acrylate 68c (Scheme 4). The methyl
ester was hydrolyzed, and acid 68d was converted into products
68−70 (Scheme 4).
Naphthodioxol-5-ol triﬂate was also used in a palladium-
catalyzed hydroxycarbonylation reaction41 to provide access to
carboxylic acid 71a, which was further converted to products
71−74 (Scheme 4). A diﬀerent route was chosen to synthesize
derivatives of naphtodioxole-6-carboxylic acid: By treating
bis(bromomethyl)benzodioxole with iodide, a highly reactive
diene was generated in situ,42 which was intercepted with
methyl acrylate in a Diels−Alder reaction. The resulting
decaline derivative 75a was oxidized with 2,3-dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ) to aﬀord naphthaline 75b.
Saponiﬁcation of the methyl ester gave carboxylic acid 75c,
which was further converted to ﬁnal products 75−77 (Scheme
4).
At 100 μM, ﬁve compounds (47, 51, 53, 72, and 73)
modulated IGABA more eﬃciently than piperine (see Figure
3A,B and Table 2). IGABA potentiation ranged from 280% ±
52% (51) to 514% ± 76% (72). IGABA enhancement by 46, 50,
52, 69, 75, 76, and 77 was less pronounced compared to
piperine [IGABA potentiation range 42% ± 1% (46) to 178% ±
30% (50)]. None of the other derivatives induced signiﬁcant
IGABA enhancement (see Figure 3A,B and Table 2).
Concentration−response curves of IGABA modulation by
linker-modiﬁed derivatives 47, 53, 56, 72, and 73 are illustrated
in Figure 3C,D. The combination of N,N-dipropyl amide from
the series 1−45 with the two most eﬃcient modiﬁcations in the
linker region (1,4-phenylene and naphthodioxol-5-yl) resulted
in 47 (IGABA‑max = 603% ± 87%, EC50 = 70.8 ± 21.1 μM), 72
(IGABA‑max = 706% ± 58%, EC50 = 102.0 ± 11.2 μM), and 73
(IGABA‑max = 480% ± 85%, EC50 = 31.8 ± 5.3 μM) inducing
stronger IGABA enhancement than piperine (Table 3). These
ﬁndings underscore the general validity of favorable N,N-
functionalization also for this series of linker-modiﬁed
compounds. However, none of the modiﬁcations led to
compounds with a higher activity than the initial parent
compound 23.
Selectivity Proﬁle. Previously, we have shown that 2434
[(2E,4E)-5-(1,3-benzodioxol-5-yl)-N,N-diisobutyl-2,4-pentadie-
namide] similarly modulates GABAA receptors containing
either β2/3 or β1 subunits, in contrast to the preferential
modulation of β2/3 receptors by piperine.
34
In the present study, analysis of the most eﬃcient piperine
derivative (23) revealed that GABAA receptors composed of
α1β2γ2S (IGABA‑max = 1673% ± 146%) and α5β2γ2S (IGABA‑max =
1624% ± 156%) subunits were more eﬃciently modulated than
receptors containing α3β2γ2S subunits (IGABA‑max = 1284.6% ±
142%; see Table 4). Signiﬁcantly weaker potentiation was
observed for receptors composed of α2β2γ2S (IGABA‑max = 980%
± 129%) and α4β2γ2S subunits (IGABA‑max = 1316% ± 55%).
Replacing the β2 subunits by β3 subunits did not signiﬁcantly
alter the strength of IGABA potentiation, whereas modulation of
GABAA receptors containing β1 subunits was signiﬁcantly less
pronounced (IGABA‑max = 1157% ± 69%; p < 0.05). In
comparison with α1β2γ2S receptors, 23 displayed an increased
potency for α2β2γ2S receptors, followed by α1β3γ2S, α3β2γ2S, and
Scheme 1. Structural Modiﬁcations of the Piperine Scaﬀold
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α4β2γ2S receptors. EC50 values for the other receptor subtypes
did not diﬀer from those for α1β2γ2S (see Figure 4A,B and
Tables 4 and 5).
Like 23, derivative 25 most eﬃciently enhanced IGABA
through GABAA receptors composed of α1β2γ2S subunits
(IGABA‑max = 760% ± 47%; see Table 4 and Figure 4C,D).
Replacing the α1 subunit by α2/3/4/5 subunits signiﬁcantly
reduced IGABA potentiation by 25 (see Table 4 and Figure 4C).
Notably, 25 displayed a more pronounced β2/3 preference
compared to piperine or 23 [inducing a 3.9-fold (α1β3γ2S) to 5-
fold (α1β2γ2S) stronger IGABA enhancement compared to
α1β1γ2S receptors]. Compound 25 showed comparable potency
for most of the tested receptor subtypes ranging from 13.8 ±
1.8 μM to 56.7 ± 21.0 μM; signiﬁcantly higher EC50 values
were estimated for α1β3γ2S receptors (see Tables 4 and 6).
These data support the previous observation that when the
cyclic piperidine residue is replaced by N,N-dialkyl moieties
such as N,N-dipropyl (23), N,N-diisopropyl (24),34 or N,N-
dibutyl (25), eﬃciency and potency can be signiﬁcantly
enhanced. However, while 2434 lost its ability to distinguish
between the β-subunit isoforms, preferential modulation of β2/3
receptors by 23 was comparable to piperine, and it was even
more pronounced for 25 (see Figure 4 B,D and Tables 4−6).
Thus, 23 and 25 displaycompared to classical GABAA
receptor modulators such as benzodiazepinesa distinct
subunit selectivity proﬁle. Unlike benzodiazepines, 23 and 25
also modulate GABAA receptors containing α4 subunits with
high eﬃciency and are not dependent on the presence of a γ2S
subunit (data not shown). Whether this subunit selectivity
proﬁle has any pharmacological relevance has to be clariﬁed in
further studies.
Scheme 2. Synthesis of Piperine Derivatives with Modiﬁcation of the Amide Function and Truncated Alkene Spacera
aConditions: (a) Amine (3.5 equiv), dry THF, rt. (b) Lawesson’s reagent, dry THF, rt. (c) LiAlH4, THF, rt.
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Structure−Activity Relationships: General Trends.
When the whole data set was analyzed, several distinct SARs
could be deduced. They are mostly related to the substitution
pattern at the amide nitrogen atom, as this was the main point
of variation in the data set. Thus, concerning N,N-dialkyl-
substituted amides, there is evidence that IGABA enhancement is
related in a nonlinear (parabolic) function to the number of
carbon atoms (Figure 5), with the optimum being dipropyl
(23). This type of parabolic relationship is quite common,
especially when it refers to a parameter that is linked to
lipophilicity of the compounds and activity data obtained in a
cellular assay. It has, for example, also been observed for a series
of capsaicin analogues with respect to their TRPV1 activation.43
Interestingly, whether the alkyl chains are linear or branched
does not reverse the order: 20 (dimethyl) < 21 (diethyl) < 23
(dipropyl)/22 (diisopropyl) < 25 (dibutyl)/2434 (diisobutyl) <
26 (dihexyl)/27 (dicyclohexyl). With respect to compounds
where the amide nitrogen atom is part of a ring,
methylpiperines 33, 34, and 35 induced the strongest IGABA
potentiation, followed by azepane amide 28 and piperine.
Interestingly, the dimethylpiperine 38 was comparably active to
the parent compound. Introduction of a second heteroatom
Figure 2. (A, B) Modulation of chloride currents through GABAA receptors composed of α1, β2, and γ2S subunits by 100 μM piperine and the
indicated derivatives (dotted line indicates cutoﬀ for highly active compounds). (C, D) Concentration-dependent IGABA (EC3−7) enhancement
through α1β2γ2S GABAA receptors, (C) for 22 (▲), 23 (●), 25 (◆), and 35 (■), ranked by eﬃciency, and (D) for 25 (○) and 43 (●), ranked by
potency, compared to piperine (dotted line). (E, F) Representative IGABA modulated by (E) 23 and (F) 25. Data represent mean ± SEM from at
least three oocytes and two oocyte batches. Asterisks indicate statistically signiﬁcant diﬀerences from zero: *p < 0.05, **p < 0.01. Data for piperine
were taken from ref 31.
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into the ring led to almost complete loss of IGABA enhancement
(N-alkylpiperazine amides 31, 32, 40, 41, and 42 and
morpholine amide 29).
Replacement of the tertiary nitrogen atom for a secondary
one, irrespective of alkyl or aryl substitution, led to a complete
loss of activity (aryl-substituted N, 1−3, 5−7, 9, and 10; alkyl-
substituted N, 4, 8, and 11−16). Reducing the H-bond
acceptor strength of the amide by synthesizing the respective
thioamide (44) abolished the modulatory activity. Reduction of
the amide to the analogous amine changed the proﬁle of the
compound from potentiation (piperine at 100 μM, 226% ±
26%)31 to inactive (45 at 100 μM, −16% ± 14%; Table 1).
With respect to the linker region, shortening the distance by
removing one vinylene unit signiﬁcantly reduced IGABA
enhancement (piperine vs 17 and 22 vs 18). All the other
modiﬁcations, such as rigidiﬁcation by inserting benzene,
thiophene, or naphthalene moieties, reduced IGABA potentiation
by at least a factor of 5 compared to 23. Interestingly, the
modulatory activity did not seem to be related to distance of
pharmacophoric substructures, such as the benzodioxole and
the amide moiety. For naphthalene analogues 72 and 65, an
increase in distance led to a decrease of activity, whereas in the
case of 22 and 18, a decrease of distance led to a decrease of
activity. Comparing 23 and 70, which show identical distance of
these two moieties, 70 completely lacks activity (32% ± 12%,
Table 1). In conclusion, the best compounds achieved in terms
of eﬃciency were the piperine analogues 22 and 23.
Computational Analysis. In order to rationalize the trends
observed in the SAR with respect to physicochemical properties
and chemical substructures, we explored the possibility to apply
quantitative structure−activity relationship (QSAR) methods.
As IGABA potentiation does not allow classical QSAR analysis,
binary classiﬁcation models were built from ﬁve methods and
three descriptor sets. For these studies, all 76 piperine
derivatives described above were employed. Sixteen com-
pounds showing ≥200% IGABA potentiation were assigned to an
active class, since they were at least as active as the lead
compound piperine. The remaining 60 ligands were assigned to
an inactive class. Classiﬁcation methods comprised instance-
based classiﬁer (IBk), J48 decision tree (J48), naiv̈e-Bayes
classiﬁer (NB), random forest (RF), and support vector
machine (SMO) implemented in the software package
WEKA.44 The software package Molecular Operating Environ-
ment (MOE) was used for calculation of 2D descriptors and
ﬁngerprints. The three descriptor sets used comprised six 2D
descriptors obtained after applying a feature selection algorithm
on the whole panel of 125 2D MOE descriptors (6D), 11
physical chemical properties (PHYSCHEM), and MACCS
ﬁngerprints (MACCS).
The statistical parameters obtained for the 15 best
classiﬁcation models are listed in Table 7. Most of the models
possess reliable quality (except models 11 and 13); that is,
values of the Matthews correlation coeﬃcient (MCC) are
higher than 0.4 and total accuracy varies from 0.7 to 0.9.
Models 3 and 4, although possessing the best statistical
performance parameters, are not discussed further, as they are
diﬃcult to interpret. Instead, models 7 and 12 are discussed in
more detail, because these models (i) show almost equal
performance, (ii) were built using descriptors of physical
chemical properties and MACCS ﬁngerprints, (iii) provide
clear separation between active and inactive instances, and (iv)
allow us to trace back the decisive chemical and structural
descriptors for the data set.
The decision tree obtained in model 7 with PHYSCHEM
descriptors (Figure 6) uses as a ﬁrst criterion for separation of
active and inactive piperine derivatives: the topological polar
surface area. By applying a threshold of 39, 25 inactive ligands
exhibiting polar substituents at the amide nitrogen were ﬁltered
out. These include compounds 1−16 with monosubstituted
amide function and compounds 29, 31, 32, 36, 37, 40−42, and
44 containing several heteroatoms (e.g., OH groups or an
additional nitrogen as in piperazines or both). Thus, application
of a single ﬁlter decreased the number of inactive ligands in the
Table 1. IGABA Modulation through α1β2γ2S GABAA
Receptors by Indicated Compounds (100 μM)a
compd
modulation of IGABA
(%) n compd
modulation of IGABA
(%) n
1 0 ± 0 3 25 506 ± 74** 3
2 10 ± 0 3 26 0 ± 0 3
3 5 ± 5 3 27 13 ± 13 3
4 −15 ± 9 3 28 294 ± 66* 3
5 −2 ± 2 3 29 0 ± 0 3
6 −7 ± 3 3 30 113 ± 17* 3
7 8 ± 7 3 31 −20 ± 20 3
8 −8 ± 6 3 32 −5 ± 5 3
9 0 ± 0 3 33 359 ± 50* 3
10 1 ± 7 3 34 439 ± 31* 3
11 51 ± 11 3 35 568 ± 54 3
12 −6 ± 6 3 36 33 ± 9 3
13 33 ± 17 3 37 26 ± 14 3
14 0 ± 0 3 38 218 ± 43* 3
15 −1 ± 17 3 39 183 ± 20** 3
16 −6 ± 6 3 40 12 ± 8 3
17 79 ± 8* 3 41 5 ± 5 3
18 66 ± 30 3 42 48 ± 12 3
20 61 ± 28 3 43 445 ± 74** 3
21 258 ± 28 3 44 17 ± 17 3
22 986 ± 244* 3 45 −16 ± 14 3
23 1091 ± 257* 3
aAll data are given as mean ± SEM. Asterisks indicate statistically
signiﬁcant diﬀerences from zero: *p < 0.05, **p < 0.01.
Table 2. IGABA Modulation through α1β2γ2S GABAA
Receptors by Indicated Compounds (100 μM)a
compd
modulation of IGABA
(%) n compd
modulation of IGABA
(%) n
46 42 ± 1** 3 62 13 ± 2 3
47 364 ± 55** 3 63 12 ± 4 3
48 49 ± 7 3 64 4 ± 4 3
49 30 ± 15 3 65 105 ± 18 3
50 178 ± 32* 3 66 67 ± 23 3
51 280 ± 52** 3 67 18 ± 9 3
52 63 ± 12* 3 68 −1 ± 12 3
53 298 ± 31** 3 69 74 ± 1* 3
54 34 ± 8 3 70 32 ± 12 3
55 79 ± 24 3 71 32 ± 10 3
56 114 ± 11 3 72 334 ± 23** 3
57 15 ± 15 3 73 514 ± 76** 3
58 −5 ± 12 3 74 60 ± 17 2
59 134 ± 39 3 75 58 ± 29* 3
60 51 ± 21 3 76 122 ± 26* 3
61 11 ± 2 3 77 138 ± 29* 3
aAll data are given as mean ± SEM. Asterisks indicate signiﬁcant
diﬀerences from zero: *p < 0.05, **p < 0.01.
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data set almost by half, from 60 to 35 compounds. In the next
branch of the decision tree, 10 compounds with less than four
rotatable bonds were excluded from the data set. These
included highly rigid piperine derivatives with linker regions
modiﬁed to either a single double bond (17) or to an aromatic
system (46, 50, 54, 58, 62, 65, 68, 71, and 75). Furthermore,
11 compounds with high lipophilicity (log P > 5.2) were
ﬁltered out: 26 and 27 with n-hexyl and cyclohexyl sustituents
at the amide nitrogen, as well as 48, 52, 56, 60, 64, 67, 70, 77,
and 63, which have dibutyl and dipropyl substituents in the
same region. The fact that the top-ranked compounds are
either N,N-dipropyl-, N,N-dibutyl-, or N,N-diisobutyl-substi-
tuted is reﬂected in the next leaf, which assigns ﬁve compounds
(23, 24,34 25, 43, and 73) with more than seven rotatable
bonds to the active class. The last two branches of the decision
tree ﬁlter out compounds on the basis of their molecular weight
and refractivity.
The decision tree obtained for model 12 with MACCS
ﬁngerprints (Figure 7) is fully in line with the one based on the
PHYSCHEM descriptor set. The ﬁrst ﬁltering criterion was
presence or absence of an NH group. It ﬁltered 21 derivatives
(1−16, 31, 32, 40, 42, and 45), most of which were those
showing high polar surface area (TPSA). The next branching
ﬁlter was presence of a sulfur atom, which removes six inactive
ligands (30, 44, and 58−61) from the data set. The next leaf
separates compounds that do not have a six-membered ring as
in piperidinyl, cyclohexyl, and morpholinyl, which led to seven
correctly classiﬁed active ligands (21−23, 24,34 25, 28, and 43)
and three missclassiﬁed inactives (18, 20, and 26). This
criterion is in line with the ﬁlter “b_rotN > 7” for active
compounds in the PHYSCHEM model.
To summarize, active piperine analogues are mainly
characterized by a topological polar surface smaller than 39,
have at least three rotatable bonds (better more than 7), and
show a log P value smaller than 5.2.
Compounds 25 and 23 Induce Anxiolysis in Mice.
Activation of TRPV1 by piperine and its derivatives may cause
unwanted side eﬀects, including changes in pain sensation and
body temperature and induction of fear that would interfere
with GABAA-mediated eﬀects
45,46 (for review see ref 47). In
order to rule out potential activation of TRPV1, selected
compounds were studied in X. laevis oocytes for interaction
with TRPV1 prior to in vivo characterization. The most potent
(25) and most eﬃcient (23) piperine analogues (Table 3,
Figure 2C,D) did not activate TRPV1 expressed in Xenopus
oocytes (upon application of 100 μM, data not shown). Both
compounds were further characterized concerning their
anxiolytic activity (see also ref 34).
As illustrated in Figure 8A, male C57BL/6N mice treated
with 23 at doses ≥0.3 mg/kg body weight spent signiﬁcantly
more time in the open arms (OA) of the elevated plus maze
(EPM) test compared to a saline-treated control group
(control, 28.7% ± 2.7% for n = 41; 23 at 0.3 mg/kg, 45.6%
± 3.2% for n = 17; p < 0.01). This eﬀect was dose-dependent
and reached its maximum at a dose of 3 mg/kg body weight,
indicating strong anxiolytic eﬀects of 23. Similarly, mice treated
with 25 also spent signiﬁcantly more time in the OA of the
EPM test at doses ≥0.3 mg/kg body weight compared to
saline-treated control littermates (control, 28.7% ± 2.7% for n
= 41; 25 at 0.3 mg/kg, 39.8% ± 4.1% for n = 23; p < 0.05;
Figure 8B). The anxiolytic eﬀect of 25 reaching its maximum at
a dose of 3 mg/kg body weight (25 at 3 mg/kg, 43.9% ± 4.3%
for n = 12), however, was less pronounced compared to 23.
Application of doses ≥10 mg/kg of 23 or 25 did not further
increase the anxiolytic eﬀect in the EPM, which is presumably
due to the concomitant occurring/developing of reduced
Scheme 3. Synthesis of Piperine Analogues Containing an Aryl Spacera
aConditions: (d) Boronic acid, Pd(PPh3)4 2 mol %, K2CO3, DME/EtOH/water, 140 °C, mw, 1 h. (e) Either (COCl)2, cat. DMF, and DCM or
EDCI·HCl, HOBt, and dry DCM, followed by amine.
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locomotor activity (see Figure 8C,D for sedative eﬀects in the
open ﬁeld test). Compared to piperine and the previously
studied 2434 (Figure 8A, shaded bars taken from ref 34),
anxiolysis induced by 23 was signiﬁcantly (p < 0.05) more
enhanced, which might reﬂect the stronger IGABA potentiation
by 23 and/or the higher potency of 23 on receptors containing
α2/3 and β3 subunits. Interestingly, the anxiolytic eﬀect of the
most potent and also more eﬃcient derivative 25 did not diﬀer
from that of piperine and 24.34 It has, thus, to be clariﬁed in
further studies to what extent derivatization of the amide
moiety aﬀects the anxiolytic properties of piperine derivatives
and whether receptors/channels other than GABAA receptors
are targeted in vivo by these compounds.
Signiﬁcant amounts of 23 and 25 were detected in mouse
plasma after intraperitoneal (ip) application (see Table 8). The
estimated plasma concentrations were below the micromolar
concentrations required for signiﬁcant IGABA potentiation of
GABAA receptors expressed in Xenopus oocytes. However,
drugs are commonly less potent on ion channels expressed in
Xenopus oocytes as compared to channels expressed in either
mammalian cells or even native tissues.48 The metabolite
formation of 23 and 25 is currently unknown. At the current
stage of our research, we cannot exclude that the observed
anxiolytic and sedative eﬀects are induced by more active
metabolites. Furthermore, the currently unknown brain-barrier
penetration of 23 and 25 and possible tissue accumulation
warrants further research.
■ CONCLUSIONS
Piperine analogues modulating GABAA receptor with the
highest eﬃciency show a tertiary amide nitrogen, substituted
with ﬂexible alkyl chains with a total of 6−8 carbon atoms.
Polar substituents as well as rigid substituents give rise to a
decrease of activity. Modiﬁcations of the linker region that lead
to rigidiﬁcation of the molecules also did not improve eﬃcacy.
Compound 23 [(2E,4E)-5-(1,3-benzodioxol-5-yl))-N,N-di-
propyl-2,4-pentadienamide] induced the strongest modulation
of GABAA receptors (maximal GABA-induced chloride current
enhancement IGABA‑max = 1673.0% ± 146.3% and EC50 = 51.7 ±
9.5 μM, vs piperine, IGABA‑max = 302% ± 27% and EC50 = 52.4 ±
9.4 μM), while 25 [(2E,4E)-5-(1,3-benzodioxol-5-yl))-N,N-
dibutyl-2,4-pentadienamide] displayed the highest potency
(EC50 = 13.8 ± 1.8 μM) but was less eﬃcient than 23
(IGABA‑max = 760% ± 47%). Both piperine analogues did not
Scheme 4. Synthesis of Piperine Analogues with (Partial) Integration of the Spacer Motif into an Aryl Corea
aConditions: (e) Either (COCl)2, cat. DMF, and DCM or EDCI·HCl, HOBt, and dry DCM, followed by amine. (f) CO, Pd(OAc)2, dppp, Hünig’s
base, DMF/water, 70 °C. (g) Methyl acrylate, Pd(OAc)2 5 mol %, phenanthroline monohydrate 5.5 mol %, NEt3, dry DMF. (h) LiOH, THF/water,
rt. (i) B2pin2, [Ir(OMe)cod]2 1.5 mol %, 4,4′-di-tert-butyl-2,2′-bipyridine 3 mol %, cyclohexane, reﬂux. (j) CuBr2, MeOH/water. (k) Methyl acrylate,
Pd(OAc)2 3 mol %, (o-tolyl)3P 6 mol %, NEt3, 80 °C. (l) Methyl acrylate, NaI, dry DMF, 90°C. (m) DDQ, benzene, 80 °C.
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activate TRPV1 and induced pronounced anxiolytic action with
little sedation, suggesting their potential use as scaﬀolds for
drug development. The established determinants of eﬃcacy
may be used for future synthesis of improved GABAA
modulators.
■ EXPERIMENTAL SECTION
Biological Activity. All experiments on animals were carried out in
accordance with the Austrian Animal Experimental Law, which is in
line with EU Directive 2010/63/EU. Every eﬀort was made to
minimize the number of animals used.
Expression of GABAA Receptors in Xenopus laevis Oocytes
and Two-Microelectrode Voltage-Clamp Experiments. Prepara-
tion of stage V−VI oocytes from X. laevis and synthesis of capped
runoﬀ poly(A) cRNA transcripts from linearized cDNA templates
(pCMV vector) was performed as previously described.49 Female X.
laevis frogs (Nasco) were anesthetized by 15 min incubation in a 0.2%
MS-222 (methanesulfonate salt of 3-aminobenzoic acid ethyl ester;
Sigma−Aldrich, Vienna, Austria) solution before removal of parts of
Figure 3. (A, B) Modulation of chloride currents through GABAA receptors composed of α1, β2, and γ2S subunits by 100 μM piperine and the
indicated derivatives (dotted line indicates cutoﬀ for highly active compounds). (C, D) Concentration-dependent IGABA (EC3−7) enhancement
through α1β2γ2S GABAA receptors: (C) by 47 (■), 53 (▲), and 72 (●), ranked by eﬃciency, and (D) by 56 (▲) and 73 (●), ranked by potency,
compared to piperine (dotted line). (E, F) Representative IGABA modulated by (E) 72 and (F) 73. Data represent mean ± SEM from at least three
oocytes and two oocyte batches. Asterisks indicate statistically signiﬁcant diﬀerences from zero: *p < 0.05, **p < 0.01. Data for piperine were taken
from ref 31.
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the ovaries. Follicle membranes from isolated oocytes were enzymati-
cally digested with 2 mg/mL collagenase (type 1A, Sigma−Aldrich,
Vienna, Austria).
Selected oocytes were injected with 10−50 nL of DEPC-treated
water (diethyl pyrocarbonate, Sigma, Vienna, Austria) containing the
diﬀerent GABAA cRNAs at a concentration of approximately 300−
3000 pg·nL−1·subunit−1.
To ensure expression of the γ2S subunit in the case of α1/2/3/5β2/3γ2S
receptors, cRNAs were mixed in a ratio of 1:1:10. For expression of
receptors composed of α4β2γ2S and α1β1γ2S, cRNAS were mixed in a
ratio of 3:1:10. The amount of cRNAs was determined by means of a
NanoDrop ND-1000 (Kisker-Biotech, Steinfurt, Germany).
Oocytes were stored at +18 °C in modiﬁed ND96 solution (90 mM
NaCl, 1 mM CaCl2, 1 mM KCl, 1 mM MgCl2·6H2O, and 5 mM
HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid], pH 7.4,
all from Sigma−Aldrich, Vienna, Austria).
Chloride currents through GABAA receptors (IGABA) were measured
at room temperature (+21 ± 1 °C) by means of a two-microelectrode
voltage clamp technique making use of a Turbo TEC-05X ampliﬁer
(npi electronic, Tamm, Germany). IGABA were elicited at a holding
potential of −70 mV. Data acquisition was carried out by means of an
Axon Digidata 1322A interface using pCLAMP v.10 (Molecular
Devices, Sunnyvale, CA). The modiﬁed ND96 solution was used as
bath solution. Microelectrodes were ﬁlled with 2 M KCl and had
resistances between 1 and 3 MΩ.
Fast Perfusion System. GABA and the studied derivatives were
applied by means of the ScreeningTool (npi electronic, Tamm,
Germany) fast perfusion system as described previously.50 To elicit
IGABA, the chamber was perfused with 120 μL of GABA- or compound-
containing solution at a volume rate of 300 μL/s.34 Care was taken to
account for possible slow recovery from increasing levels of
desensitization in the presence of high drug concentrations. The
duration of washout periods was therefore extended from 1.5 min
(<10 μM compounds) to 30 min (≥10 μM compounds). Oocytes
with maximal current amplitudes >3 μA were discarded to exclude
voltage clamp errors.
Data Analysis: GABAA Receptors. Stimulation of chloride
currents by modulators of the GABAA receptor was measured at a
GABA concentration eliciting between 3% and 7% of the maximal
current amplitude (EC3−7). The GABA EC3−7 was determined for
each oocyte individually. Enhancement of the chloride current was
deﬁned as (IGABA+compd/IGABA) − 1, where IGABA+compd is the current
response in the presence of a given compound and IGABA is the control
GABA current. IGABA‑max reﬂects the maximal IGABA enhancement.
Concentration−response curves were generated and the data were
ﬁtted by nonlinear regression analysis using Origin Software
(OriginLab Corp.). Data were ﬁtted to the equation 1/(1 + (EC50/
[compound])nH), where nH is the Hill coeﬃcient. Each data point
represents the mean ± SEM from at least three oocytes and ≥2 oocyte
batches. Statistical signiﬁcance was calculated by paired Student t-test
with a conﬁdence interval of <0.05.
Molecular Modeling and Quantitative Structure−Activity
Relationships. Data Set. The 2D structures of 76 piperine
derivatives and piperine were drawn in the InstantJChem package
for Excel (www.chemaxon.com/products/jchem-for-excel) and ex-
ported in sdf format. The LigPrep tool provided by Schrödinger in the
Maestro package (Maestro, version 9.2; Schrödinger LLC, New York,
2011) was used to generate low-energy 3D structures and protonated
states. All possible stereoisomers per ligand were computed and one
low-energy conformation was generated per each stereoisomer in
MMFF force ﬁeld. The protonated states were determined at pH 7.4
(pH used in the experiments). For compounds 33, 34, 36, 38, and 39,
several stereisomers were determined. Since these structures were not
ionizable at this pH, the stereoisomers were considered equal in terms
of 2D structure and duplicates were removed. Subsequently, the
structures were imported into MOE, where partial atomic charges
were calculated in the MMFF94 force ﬁeld. Piperine (obtained from
Sigma−Aldrich, Vienna, Austria) was used as a reference compound to
determine the class labels of its derivatives. Potentiation of GABA
current by piperine was 226% ± 26%;31 therefore, compounds with
potentiation ≥200% were assigned to the active class, otherwise to the
inactive. This led to an unbalanced data set with 17 “active” and 60
“inactive” compounds.
Descriptor Sets. One hundred forty-three 2D descriptors
implemented in MOE were calculated. The full list is provided in
Supporting Information (Table S1A). Descriptors showing no variance
were removed from the data set, and the remaining 125 descriptors
(Supporting Information, Table S1B) underwent feature selection by
the BestFirst algorithm implemented in the software package WEKA
version 3.7.9. Consequently, the six descriptors left (set 6D) were used
for further classiﬁcation studies (Table 9). Additionally, as a reference
descriptor set, we used 11 descriptors of physicochemical properties
(set PHYSCHEM) from the list of 125 descriptors described above
(Table 10). These descriptors allow us to trace molecular features
important for biological activity and have previously shown good
performance in application to ligand-based studies.51 As an attempt to
trace the structural features relevant to the activity of piperine
derivatives, MACCS ﬁngerprints (MACCS Keys; MDL Information
Systems, Inc., San Leandro, CA) were computed in MOE. MACCS are
a set of structural keys, where each key describes a small substructure
consisting of up to 10 non-hydrogen atoms. A Python script
(Supporting Information) was applied to divide the ﬁngerprints into
bit strings. The latter were further used in the classiﬁcation studies as
descriptor set “MACCS”.
Table 3. Eﬃciency and Potency of Further Characterized
Piperine Derivatives and Piperinea
compd IGABA‑max (%) EC50 (μM) nH n
piperine 302 ± 27 52.4 ± 9.3 1.5 ± 0.2 3
22 1581 ± 74** 86.7 ± 13.9 2.3 ± 0.2 6
23 1673 ± 146** 51.7 ± 9.5 3.1 ± 0.8 6
25 760 ± 47** 13.8 ± 1.8** 1.8 ± 0.1 6
35 733 ± 60** 67.7 ± 11.0 1.9 ± 0.3 6
43 505 ± 24** 23.1 ± 3.3* 1.6 ± 0.2 6
47 603 ± 87* 70.8 ± 21.1 1.2 ± 0.2 3
53 388 ± 64 55.3 ± 17.6 1.5 ± 0.2 3
56 165 ± 4** 36.8 ± 2.0 1.2 ± 0.0 3
72 706 ± 58** 102.0 ± 11.2 1.9 ± 0.2 5
73 480 ± 85 31.8 ± 5.3 2.7 ± 0.2 6
aFrom ref 31, including number of experiments n. Asterisks indicate
signiﬁcant diﬀerences from piperine: *p < 0.05; **p < 0.01.
Table 4. Eﬃciency and Potency of 23 and 25 on GABAA
Receptors of Diﬀerent Subunit Compositionsa
receptor subtype IGABA,max (%) EC50 (μM) nH n
Compound 23
α1β1γ2S 1157 ± 69* 57.5 ± 7.3 1.8 ± 0.1 5
α1β2γ2S 1673 ± 146 51.7 ± 9.5 3.1 ± 0.8 6
α1β3γ2S 1240 ± 128 34.7 ± 5.7 1.9 ± 0.2 5
α2β2γ2S 980 ± 129** 26.4 ± 6.6 1.9 ± 0.4 6
α3β2γ2S 1285 ± 142 36.6 ± 7.2 1.9 ± 0.3 5
α4β2γ2S 1316 ± 55* 34.7 ± 3.8 1.7 ± 0.1 7
α5β2γ2S 1624 ± 156 61.9 ± 10.4 1.4 ± 0.1 7
Compound 25
α1β1γ2S 152 ± 30** 15.9 ± 4.9 1.3 ± 0.6 5
α1β2γ2S 760 ± 47 13.8 ± 1.8 1.8 ± 0.1 8
α1β3γ2S 587 ± 8** 29.5 ± 2.9** 1.5 ± 0.1 4
α2β2γ2S 512 ± 26** 14.8 ± 1.9 2.2 ± 0.3 4
α3β2γ2S 617 ± 42* 16.0 ± 2.7 1.8 ± 0.1 6
α4β2γ2S 419 ± 73** 56.7 ± 21.0 1.3 ± 0.3 4
α5β2γ2S 387 ± 20** 17.2 ± 1.4 1.7 ± 0.2 5
aAsterisks indicate signiﬁcant diﬀerences from α1β2γ2S receptor
subtype as follows: *p < 0.05; **p < 0.01.
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Computational Methods. As classiﬁcation methods, instance-based
classiﬁer (IBk), J48 decision tree (J48), naiv̈e-Bayes classiﬁer (NB),
random forest (RF), and Support vector machine (SMO) were used as
implemented in Weka. All methods were used with the default
parameter settings. Nevertheless, diﬀerent costs were associated with
misclassiﬁed compounds since the data set was unbalanced. The costs
were evaluated by use of an in-house script (Supporting Information),
which consequently built models with diﬀerent costs of the false
positive (FP) and false negative (FN) compounds (from 1 to 200 with
step of 1 for FN and from 0 to 20 with step of 0.1 for FP). Moreover,
inside the script the 10-fold cross-validation was applied and statistical
parameters were computed. Subsequently, one model per method and
descriptor set was selected on the basis of highest values of MCC,
accuracy, sensitivity, and speciﬁcity and was taken for visual inspection
and possible interpretation. The cost-sensitive parameters obtained for
the best 15 models are listed in Table 11.
Statistical Parameters. The statistical parameters of every model
were calculated on the basis of values from confusion matrix (for
details see ref 52), where TP and TN stand for correctly classiﬁed
active and inactive compounds and FP and FN for misclassiﬁed
inactive and active ligands. The true-positive rates of active
(sensitivity) and inactive (speciﬁcity) classes were calculated by the
following formulas:
Figure 4. Analysis of subunit preferential IGABA enhancement by (A, B) the most eﬃcient (23) and (C, D) the most potent (25) piperine derivatives.
(E, F) Representative IGABA through seven GABAA receptor subtypes by 23 at 100 μM. Data represent mean ± SEM from at least three oocytes and
two oocyte batches.
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=
+
sensitivity
TP
TP FN
=
+
specificity
TN
TN FP
The accuracy of the model was deﬁned as the ratio of correctly
predicted compounds to the total amount of compounds.
= +accuracy TP TN
total
Additionally, the Matthews correlation coeﬃcient (MCC) was used to
assess the quality of the obtained models. It was calculated from the
formula
= · − ·
+ + + +
MCC
TP TN FP FN
(TP FP)(TP FN)(TN FP)(TN FN)
MCC is independent of the class sizes and therefore gives a rational
evaluation of prediction in our case. It can return values from −1 to
+1, where +1 determines perfect prediction, 0 means random
classiﬁcation, and −1 represents a total misclassiﬁcation. The value
of 0.4 was taken as a threshold to ﬁlter the best-performing models.
Behavioral Studies. Male mice (C57BL/6N) were obtained from
Charles River Laboratories (Sulzfeld, Germany). For maintenance,
mice were group-housed (maximum ﬁve mice per type IIL cage) with
free access to food and water. At least 24 h before the commencement
of experiments, mice were transferred to the testing facility, where they
were given free access to food and water. The temperature in the
maintenance and testing facilities was 23 ± 1 °C; the humidity was
40−60%; a 12 h light−dark cycle was in operation (lights on from
07:00 to 19:00). Only male mice aged 3−6 months were tested.
Compounds were applied by intraperitoneal (ip) injection 30 min
before each test. Testing solutions were prepared in a solvent
composed of 0.9% NaCl solution with 10% dimethyl sulfoxide
(DMSO) and 3% Tween 80. Application of the solvent alone did not
inﬂuence animal behavior. All doses are indicated as milligrams per
kilogram of body weight of the animal.
Elevated Plus Maze Test. The animals’ behavior was tested over 5
min on an elevated plus maze 1 m above ground consisting of two
closed and two open arms, each 50 × 5 cm in size. The test instrument
was built from gray PVC; the height of closed arm walls was 20 cm.
Illumination was set to 180 Lux. Animals were placed in the center,
facing an open arm. Analysis of open and closed arm entries and time
on open arm was automatically done with Video-Mot 2 equipment and
software (TSE Systems, Bad Homburg, Germany).34
Open Field Test. Ambulation was tested over 10 min in a 50 × 50
cm ﬂexﬁeld box equipped with infrared rearing detection. Illumination
was set to 150 Lux. The animals’ explorative behavior was analyzed by
use of the ActiMot 2 equipment and software (TSE-systems, Bad
Homburg, Germany). Arenas were subdivided into border (up to 8 cm
from wall), center (20 × 20 cm, 16% of total area), and intermediate
area according to the recommendations of EMPRESS (European
Table 5. Comparison of Potency and Eﬃciency of 23 for GABAA Receptors of Diﬀerent Subunit Compositions
a
α1β2γ2S α1β1γ2S α1β3γ2S α2β2γ2S α3β2γ2S α4β2γ2S α5β2γ2S
P E P E P E P E P E P E P E
α1β2γ2S * ** *
α1β1γ2S ** * * *
α1β3γ2S *
α2β2γ2S ** * **
α3β2γ2S
α4β2γ2S *
α5β2γ2S
aPotency (P), expressed as EC50, and eﬃciency (E), expressed as IGABA‑max, are compared. Asterisks indicate statistical signiﬁcance as follows: *p <
0.05, **p < 0.01.
Table 6. Comparison of Potency and Eﬃciency of 25 for GABAA Receptors of Diﬀerent Subunit Compositions
a
α1β2γ2S α1β1γ2S α1β3γ2S α2β2γ2S α3β2γ2S α4β2γ2S α5β2γ2S
P E P E P E P E P E P E P E
α1β2γ2S ** ** ** ** * ** **
α1β1γ2S * ** ** ** * **
α1β3γ2S ** * ** ** **
α2β2γ2S **
α3β2γ2S * **
α4β2γ2S
α5β2γ2S
aPotency (P), expressed as EC50, and eﬃciency (E), expressed as IGABA‑max, are compared. Asterisks indicate statistical signiﬁcance as follows: *p <
0.05, **p < 0.01.
Figure 5. Relation between log(potentiation of IGABA) of dialkyl-
substituted piperine derivatives at the amide nitrogen and number of
carbon atoms at this region. Data for 24* were taken from ref 34.
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Mouse Phenotyping Resource of Standardised Screens; http://
empress.har.mrc.ac.uk).
Estimation of Plasma Levels. Trunk blood from male C57BL/6N
(6 months) was taken 15, 30, and 60 min after ip application of 23 and
25 (doses 1, 3, and 10 mg/kg body weight; injection solutions were
prepared as described for behavioral analysis). At each time point, mice
were euthanized and blood samples (500−800 μL) were collected and
compiled into ethylenediaminetetraacetic acid (EDTA)-coated micro-
tubes (1.6 mg of EDTA/sample) and centrifuged at 12 000 rpm for 5
min at 4 °C. Plasma samples were transferred into 1.5 mL tubes and
stored at −80 °C until analysis.
Materials. All solvents used were of UPLC grade. Acetonitrile and
dimethyl sulfoxide (DMSO) were supplied by Scharlau (Barcelona,
Spain). Methanol was from Lab-Scan (Gliwice, Poland). Ammonium
formate, formic acid and triﬂuoroacetic acid (TFA) were purchased
from BioSolve (Valkenswaard, Netherlands), and HPLC-grade water
was obtained from an EASYpure II (Barnstead, Dubuque, IA) water
puriﬁcation system. Blank K3EDTA C57BL/6N mouse plasma was
collected for generating plasma calibrators and quality controls (QC).
Preparations of Calibrators and Quality Control Samples. Two
separate sets of 23 and 25 stock solutions were prepared in DMSO for
making calibrators and quality control (QC) samples. Plasma
calibrators were prepared by spiking corresponding stock solutions
into a blank plasma sample. The following 23 and 25 concentrations
were added: 20, 50, 100, 250, 500, 1000, and 2000 ng/mL. The same
blank plasma and both stock solutions (for QC) were used to generate
three level plasma QC samples at 60, 1000, and 1600 ng/mL for both
23 and 25.
Table 7. Statistical Parameters of the 15 Best Models Obtained after 10-Fold Cross-Validation
model classiﬁcation method TP, TN, FP, FNa sensitivity speciﬁcity accuracy MCC, ROC
Descriptor Set 6D
1 IBk 12, 52, 8, 5 0.706 0.867 0.831 0.542, 0.825
2 J48 15, 46, 14, 2 0.882 0.767 0.792 0.556, 0.818
3 NB 16, 49, 11, 1 0.941 0.817 0.844 0.659, 0.831
4 RF 13, 52, 8, 4 0.765 0.867 0.844 0.588, 0.838
5 SMO 16, 39, 21, 1 0.941 0.650 0.714 0.491, 0.796
Descriptor Set PHYSCHEM
6 IBk 10, 52, 8, 7 0.588 0.867 0.805 0.446, 0.749
7 J48 15, 46, 14, 2 0.882 0.767 0.792 0.556, 0.828
8 NB 15, 40, 20, 2 0.882 0.667 0.714 0.457, 0.828
9 RF 15, 46, 14, 2 0.882 0.767 0.792 0.556, 0.811
10 SMO 15, 36, 24, 2 0.882 0.600 0.662 0.400, 0.741
Descriptor Set MACCS
11 IBk 9, 45, 15, 8 0.529 0.750 0.701 0.250, 0.619
12 J48 12, 48, 12, 5 0.706 0.800 0.779 0.453, 0.797
13 NB 12, 42, 18, 5 0.706 0.700 0.701 0.345, 0.713
14 RF 13, 43, 17, 4 0.765 0.717 0.727 0.409, 0.730
15 SMO 10, 56, 4, 7 0.588 0.933 0.857 0.561, 0.761
aTP = true positive, TN = true negative, FP = false positive, FN = false negative.
Figure 6. Decision tree obtained for the data set of 76 piperine
derivatives with PHYSCHEM descriptor set.
Figure 7. Decision tree obtained for the data set of 76 piperine
derivatives with MACCS ﬁngerprints.
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Two internal standard (IS) stock solutions of 22 and 24 were
prepared in DMSO in order to generate working solutions (WS) at
200 ng/mL in methanol.
Sample Preparation for UHPLC-MS/MS Analysis. Plasma proteins
were precipitated by the addition of 50 μL of WS at 200 ng/mL of the
corresponding IS: 22 (for 23) or 24 (for 25) and 500 μL of ice-cold
acetonitrile to 20 μL of K3EDTA mouse plasma. Samples were
vortexed at 1400 rpm for 10 min and then centrifuged at 13200g for 20
min at 10 °C. The supernatant was transferred into a 96-deep-well
plate for drying under nitrogen gas ﬂow (Evaporex EVX-96, Apricot
Designs, Monrovia, CA) and redissolved in 200 μL of injection solvent
(65% 10 mM ammonium formate + 0.05% formic acid, 35%
acetonitrile + 0.05% formic acid) before MS/MS analysis.
LC-MS/MS Analyses. Quantiﬁcation was performed on a 1290
Inﬁnity LC system coupled with a 6460 triple quadrupole mass
spectrometer with Jet Stream Technology, and data was processed
with a MassHunter Workstation Software version B.06.00 (Agilent;
Waldbronn, Germany). The 1290 Inﬁnity LC system was equipped
with a binary capillary pump, degasser, autosampler, autosampler
thermostat, thermostated column compartment, and FlexCube.
Separation was performed at 55 °C on a Kinetex XB-C18 column,
100 × 2.1 mm, 1.7 μm particle size (Phenomenex; Torrance, CA);
mobile phase of (A) 0.05% formic acid in 10 mM ammonium formate
Figure 8. Compounds 23 and 25 display anxiolytic eﬀects in the EPM test and little sedation in the OF test. Bars indicate time spent in open arms
(OA) as a percentage of the total time 30 min after ip application of the indicated dose (in milligrams per kilogram of body weight) of (A) 23 and
(B) 25 and the total ambulation after application of (C) 23 and (D) 25. White bars illustrate the behavior of control mice. Bars represent means ±
SEM from at least eight diﬀerent mice. Asterisks indicate statistically signiﬁcant diﬀerences to control *p < 0.05, **p < 0.01 [analysis of variance
(ANOVA) with Bonferroni]. Shaded bars for the behavioral eﬀects of piperine are taken from ref 34. Behavioral experiments comparing the sedative
and anxiolytic potential of piperine, 23, and 25 have been conducted in parallel.
Table 8. Estimated Plasma Levels of Derivatives 23 and 25
after Intraperitoneal Applicationa
applied dose (mg/kg body weight) mean plasma concn (ng/mL) n
Compound 23
1 60.6 ± 14.5 3
3 194.0 ± 50.2 3
10 593.0 ± 92.4 3
Compound 25
1 41.5 ± 8.7 3
3 172.0 ± 19.0 3
10 419.0 ± 37.2 3
aData are given as mean ± SEM; n indicates the number of animals
used.
Table 9. Set of Six 2D Descriptors Selected by BestFirst
Algorithm for Classiﬁcation Studies
name deﬁnition
density molecular mass density: weight divided by vdw_vol
(amu/Å3)
lip_don no. of OH and NH atoms
opr_brigid no. of rigid bonds53
PEOE_RPC+
numeric
relative positive partial charge: largest positive qi divided by
the sum of positive qi
PEOE_VSA+3 sum of vi where qi is in the range [0.15, 0.20)
SMR molecular refractivity (including implicit hydrogens)a
aThis property is an atomic contribution model54 that assumes the
correct protonation state (washed structures). The model was trained
on ∼7000 structures and results may vary from the mr descriptor.
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and (B) 0.05% formic acid in ACN, gradient 40% B for 1 min, linear
gradient to reach 88% B after 5.3 min, shifted to 100% B for 1 min,
and back to equilibrium condition of 40% B for 0.7 min; ﬂow rate of
0.5 mL/min; total run time of 7 min. Sample injected volume was 1 μL
and autosampler was set at 10 °C. Needle wash solution was MeOH/
ACN/IPA/H2O (1:1:1:1 v/v/v/v). Flexible cube was set at a ﬂow rate
of 1 mL/min for 20 s.
MS parameters were manually optimized as follow: drying N2 gas of
320 °C at a ﬂow rate of 10 L/min, nebulizer pressure of 20 psi, sheath
N2 gas of 400 °C at a ﬂow rate of 11 L/min, nozzle voltage of 0 V,
capillary voltage of 2.5 kV, and delta EMV 0 V. Quantiﬁcation was
determined in multiple reaction monitoring (MRM) mode with an
ESI-MS/MS system in positive ionization mode. The MRM transitions
of both 23 and 25 and corresponding internal standard were as shown
in Table S2 (Supporting Information).
Syntheses. Details of synthesis and characterization of selected
products 25, 51, and 62 and key intermediates 65a, 68a−c, 71a, and
75a,b are described below. Synthetic procedures and characterization
data for all other compounds are included in Supporting Information.
Purity was determined either by elemental analysis or by HPLC and
was >95%. Unless otherwise noted, chemicals were purchased from
commercial suppliers and used without further puriﬁcation. Microwave
reactions were performed on a Biotage Initiator Sixty microwave unit
(Biotage AB, Uppsala, Sweden). Flash column chromatography was
performed on silica gel 60 from Merck (40−63 mm), whereas most
separations were performed by using a Büchi Sepacore medium-
pressure liquid chromatography (MPLC) system with a 9g column
(Buchi Labortechnik AG, Flawil, Switzerland). For thin-layer
chromatography (TLC), aluminum-backed silica gel was used. Melting
points were determined by using a Koﬂer-type Leica Galen III micro
hot stage microscope (Aigner-Unilab Laborfachhandel GmbH, Vienna,
Austria) and are uncorrected. For compounds unknown in the
literature, either high-resolution mass spectrometry (HR-MS) or
combustion analysis was performed. HR-MS was performed by E.
Rosenberg at the Institute for Chemical Technologies and Analytics,
Vienna University of Technology; all samples were analyzed by liquid
chromatography/ion trap time-of-ﬂight mass spectrometry (LC/IT-
TOF-MS) in positive or negative ion detection mode with the
recording of MS and MS/MS spectra. Combustion analysis was carried
out in the Microanalytical Laboratory, Institute of Physical Chemistry,
University of Vienna. NMR spectra were recorded on a Bruker AC 200
(200 MHz), a Bruker Avance DP160 (200 MHz), or a Bruker Avance
400 (400 MHz) spectrometer (Bruker GmbH, Vienna, Austria) and
chemical shifts are reported in parts per million (ppm). For
assignment of 13C multiplicities, standard 13C distortionless enhance-
ment by polarization transfer (DEPT) or attached proton test (APT)
spectra were recorded. HPLC analyses were performed on a Agilent
1200 HP-LC system with a Kinetex XB-C18, 2.6 μm, 50 × 2.1 mm
column (Agilent Technologies GmbH, Vienna, Austria). The mobile
phase was composed of ACN/water (gradient 50:50 up to 95:5 v/v)
with 0.1% AcOH added. GC−MS runs were performed on a Thermo
Finnigan Focus GC/DSQ II with a standard capillary column BGB 5
(30 m × i.d. 0.32 mm; Fisher Scientiﬁc GmbH, Vienna, Austria).
(2E,4E)-5-(1,3-Benzodioxol-5-yl)-N,N-dibutyl-2,4-pentadienamide
(25). Piperic acid chloride (218 mg, 1 mmol) was dissolved in 2.5 mL
of dry THF. Dibutylamine (595 μL, 3.5 mmol) was added and the
reaction mixture was stirred overnight at rt. After evaporation of the
solvent, the residue was taken up in ethyl acetate (EtOAc; 40 mL) and
washed two times each with 5% NaHCO3 and 2 N HCl. The organic
layer was separated, dried with sodium sulfate, ﬁltered, and evaporated.
The pure product was obtained after recrystallization from ethanol.
Yield 76% (746 mg, 2.26 mmol), light brown crystals, mp 88−90
°C. 1H NMR (CDCl3, 200 MHz) δ 0.85−1.05 (m, 6H, CH3), 1.22−
1.45 (m, 4H, CH2), 1.46−1.71 (m, 4H, CH2), 3.25−3.47 (m, 2H,
CH2), 5.98 (s, 2H, O−CH2−O), 6.35 (d, J = 14.6 Hz, 1H, H2), 6.70−
6.85 (m, 3H), 6.86−6.95 (m, 1H), 7.00 (d, J = 7.9 Hz, 1H), 7.36−7.54
(m, 1H). 13C NMR (CDCl3, 50 MHz) δ 14.1 (q, CH3), 14.1 (q, CH3),
20.3 (t, CH2), 20.5 (t, CH2), 30.3 (t, CH2), 32.2 (t, CH2), 46.8 (t, N−
CH2), 48.1 (t, N−CH2), 101.5 (t, O−CH2−O), 105.9 (d), 108.7 (d),
120.5 (d), 122.7 (d), 125.6 (d), 131.2 (s), 138.6 (d), 142.6 (d), 148.3
(s, C−O), 148.4 (s, C−O), 166.3 (s, CO−N). Anal. Found, C 71.96,
H 7.91, N 3.95; Calcd (·0.23H2O), C 72.01, H 8.30, N 4.20.
3-(Benzo[d][1,3]dioxol-5-yl)-N,N-dipropylbenzamide (51). Benzo-
dioxol-5-boronic acid (138 mg, 0.83 mmol, 1 equiv), 51a (237 mg,
0.83 mmol, 1 equiv), Pd(PPh3)4 (19 mg, 2 mol %), and sodium
carbonate (615 mg, 5.81 mmol, 7 equiv) were charged into a
microwave vial. Then a mixture of dimethyl ether (DME)/EtOH 5:1
(6.4 mL) and water (1.8 mL) was added, and the resulting suspension
was degassed by passing through argon for 5 min. The vial was sealed
and heated to 140 °C for 1 h in the microwave. After cooling to rt, the
reaction mixture was extracted with dichloromethane (DCM), the
solvent was evaporated, and the crude product was directly subjected
to column chromatography with light petroleum (LP)/EtOAc mixture
as eluent.
Yield 60% (163 mg, 0.50 mmol), colorless oil. TLC 0.24 (LP/
EtOAc 4:1). 1H NMR (CDCl3, 200 MHz) δ 0.76−0.98 (br m, 6H,
CH3), 1.57−1.67 (br m, 4H, CH2), 3.20−3.47 (br m, 4H, N−CH2−),
6.00 (s, 2H, O−CH2−O), 6.86−6.90 (m, 1H, ArH), 7.03−7.08 (m,
2H, ArH), 7.25−7.30 (m, 1H, ArH), 7.42 (t, J = 7.4 Hz, 1H, ArH),
7.48−7.54 (m, 2H, ArH). 13C NMR (CDCl3, 50 MHz) δ 11.1 (q,
CH3), 11.4 (q, CH3), 20.7 (t, CH2), 22.0 (t, CH2), 46.3 (t, CH2), 50.7
Table 10. Eleven Descriptors of Physical Chemical
Properties Used in the Study
name deﬁnition
a_acc no. of hydrogen-bond acceptor atoms
a_don no. of hydrogen-bond donor atoms
b_rotN no. of rotatable bondsa
log_P(o/w) log of octanol/water partition coeﬃcientb
mr molecular refractivity (including implicit hydrogens)c
PEOE_VSA_HYD total hydrophobic van der Waals surface area
TPSA polar surface aread (Å2)
vsa_acc approximate sum of VDW surface areas (Å2) of pure
hydrogen-bond acceptors
vsa_don approximate sum of VDW surface areas (Å2) of pure
hydrogen-bond donors
vsa_hyd approximate sum of VDW surface areas (Å2) of
hydrophobic atoms
Weight molecular weight (including implicit hydrogens) (amu)
aA bond is rotatable if it has order 1, is not a ring, and has at least two
heavy neighbors. bCalculated from a linear atom-type model with r2 =
0.931. cCalculated from an 11-descriptor linear model with r2 = 0.997.
dCalculated from group contributions to approximate the polar surface
area from connection table.
Table 11. Cost-Sensitive Parameters
method cost FP cost FN
Descriptor Set 6D
IBk 1 1
J48 6 1
NB 5 3
RF 9 5
SMO 52 19.1
Descriptor Set PHYSCHEM
IBk 1 1
J48 18 11
NB 1 1
RF 21 2
SMO 49 18.1
Descriptor Set MACCS
IBk 3 2
J48 29 12
NB 1 8
RF 4 1
SMO 3 2.2
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(t, CH2), 101.2 (t, O−CH2−O), 107.6 (d), 108.6 (d), 120.7 (d), 124.8
(d), 124.9 (d), 127.4 (d), 128.8 (d), 134.8 (s), 137.9 (s), 141.1 (s),
147.3 (s), 148.2 (s), 171.6 (s, −CO−N). HR-MS [M + H]+ m/z
(pred) = 326.1751, m/z (meas) = 326.1749, diﬀerence = −0.61 ppm.
[5-(Benzo[d][1,3]dioxol-5-yl)naphthalen-1-yl](piperidin-1-yl)-
methanone (62). 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (EDCI·HCl; 65 mg, 0.34 mmol, 2 equiv) was added
to a suspension of 62a (50 mg, 0.17 mmol, 1 equiv) and
hydroxybenzotriazole (HOBt; 52 mg, 0.34 mmol, 2 equiv) in dry
dichloromethane (2 mL) under argon at rt. After 2 h, the suspension
was transformed into an opaque solution and TLC indicated full
consumption of the starting material. Piperidine (0.5 mL) was added
at rt and stirring was continued overnight. After full conversion was
detected by TLC, the reaction mixture was diluted with EtOAc (30
mL); washed with 0.5 N HCl, saturated NaHCO3, and brine (20 mL
each); dried with sodium sulfate; and evaporated. The crude product
was puriﬁed by column chromatography with LP/EtOAc mixture as
eluent.
Yield 62% (0.11 mmol, 38 mg), colorless solid, mp 150−153 °C.
TLC 0.09 (LP/EtOAc 4:1). 1H NMR (CDCl3, 200 MHz) δ 1.40−1.50
(m, 2H, CH2), 1.66−1.80 (m, 4H, CH2), 3.15−3.21 (m, 2H, N−
CH2), 3.87−3.93 (m, 2H, N−CH2), 6.04 (s, 2H, O−CH2−O), 6.93−
6.95 (m, 3H, ArH), 7.39−7.56 (m, 4H, ArH), 7.84 (d, J = 8.3 Hz, 1H,
ArH), 7.94 (dd, J1 = 7.2 Hz, J2 = 2.6 Hz, 1H, ArH). 13C NMR (CDCl3,
50 MHz) δ 24.6 (t, CH2), 25.9 (t, CH2), 26.7 (t, CH2), 42.7 (t, N−
CH2), 48.3 (t, N−CH2), 101.2 (t, O−CH2−O), 108.2 (d), 110.6 (d),
123.3 (d), 123.4 (d), 124.4 (d), 125.3 (d), 126.2 (d), 126.9 (d), 127.4
(d), 120.9 (s), 131.9 (s), 134.3 (s), 135.2 (s), 140.3 (s), 147.0 (s),
147.5 (s), 169.4 (s, CO−N). HR-MS [M + H]+ m/z (pred) =
360.1594, m/z (meas) = 360.1597, diﬀerence = 0.83 ppm.
(E)-Methyl 3-(Naphtho[2,3-d][1,3]dioxol-5-yl)acrylate (65a). For
synthesis of 65a, a modiﬁcation of a previously published method38
was employed. A 8-mL vial with magnetic stirrer, screw cap, and
septum was charged with naphtho[2,3-d][1,3]dioxol-5-yl triﬂuorome-
thanesulfonate (synthesized according to ref 37) (480 mg, 1.5 mmol, 1
equiv), 1,10-phenanthroline monohydrate (16 mg, 0.083 mmol, 5.5
mol %), palladium(II) acetate (17 mg, 0.075 mmol, 5 mol %), and
anhydrous N,N-dimethylformamide (DMF, 5 mL). Then triethyl-
amine (250 μL, 1.8 mmol, 1.2 equiv) and methyl acrylate (680 μL, 7.5
mmol, 5 equiv) were added successively. The vial was ﬂushed with
argon and heated to 80 °C for 16 h. Reaction control by TLC showed
full conversion. The solvent was evaporated, and the residue was taken
up in DCM and adsorbed on silica. Column chromatography (45 g of
SiO2, eluent LP/EtOAc, 5% isocratic) yielded the pure product.
Yield 95% (364 mg, 1.425 mmol), colorless solid, mp 125−126 °C.
TLC 0.44 (LP/EtOAc 4:1). 1H NMR (CDCl3, 200 MHz) δ 3.82 (s,
3H, CH3), 5.99 (s, 2H, O−CH2−O), 6.43 (d, J = 15.7 Hz, 1H, H3),
7.04 (s, 1H, ArH), 7.25 (t, J = 7.7 Hz, 1H, H7′), 7.38 (s, 1H, ArH),
7.52 (d, J = 7.1 Hz, 1H, ArH), 7.61 (d, J = 8.1 Hz, 1H, ArH), 8.29 (d, J
= 15.7 Hz, 1H, H2). 13C NMR (CDCl3, 50 MHz) 51.7 (q, CH3), 99.9
(d), 101.4 (t, O−CH2−O), 104.4 (d), 119.9 (d), 123.5 (d), 124.0 (d),
128.7 (s), 129.5 (d), 130.7 (s), 130.9 (s), 142.1 (d), 147.6 (s), 148.6
(s), 167.3 (s, COOR). HR-MS [M − MeOH]+ m/z (pred) =
225.0546, m/z (meas) = 225.0553, diﬀerence = 3.11 ppm.
4,4,5,5-Tetramethyl-2-(naphtho[2,3-d][1,3]dioxol-6-yl)-1,3,2-di-
oxaborolane (68a). For synthesis of 68a, a modiﬁcation of a
procedure published by Ishyama et al.39 was used. A three-necked ﬂask
with magnetic stirrer, septum, reﬂux condenser, and balloon was
charged with naphtho[2,3-d][1,3]dioxole (1.72 g, 10 mmol, 1 equiv),
bis(pinacolato)diboron (1.27 g, 5 mmol, 0.5 equiv), [Ir(OMe)cod]2
(100 mg, 0.15 mmol, 1.5 mol %), and 4,4′-di-tert-butyl-2,2′-bipyridine
(81 mg, 0.3 mmol, 3 mol %) and ﬂushed with argon. Then
cyclohexane (60 mL) was added and the reaction was heated to reﬂux
and monitored with GC/MS. After 24 h the reaction did not proceed
any further. After evaporation of the solvent, the residue was
redissolved in DCM, adsorbed on silica, and directly subjected to
column chromatography (45 g of SiO2, eluent LP/EE 30:1), which
yielded the pure product (683 mg of starting material could be
reisolated in this step).
Yield 29% (48% based on recovered starting material, 874 mg, 2.9
mmol), colorless solid, mp 97−99 °C. TLC 0.18 (LP/EE 30:1). 1H
NMR (CDCl3, 200 MHz) δ 1.38 (s, 12H, CH3), 6.03 (s, 2H, O−
CH2−O), 7.10 (s, 1H), 7.64 (d, J = 8.2 Hz, 1H), 7.70 (d, J = 8.2 Hz,
1H), 8.16 (s, 1H, H5). 13C NMR (CDCl3, 50 MHz) 24.9 (q, 4C,
CH3), 83.8 (s, B−O−CR3), 101.0 (t, O−CH2−O), 103.8 (d), 104.4
(d), 126.2 (d), 129.3 (d), 129.8 (s), 132.5 (s), 134.9 (d), 147.4 (s),
148.4 (s); C6 signal could not be detected due to low signal intensity.
6-Bromonaphtho[2,3-d][1,3]dioxole (68b). For synthesis of 68b, a
modiﬁcation of a published procedure40 was used. In a three-necked
ﬂask with magnetic stirrer and reﬂux condenser, 68a (700 mg, 2.35
mmol, 1 equiv) was dissolved in methanol. Copper(II) bromide (1.57
g, 7 mmol, 3 equiv) was dissolved in water (20 mL) and added. The
reaction was heated to reﬂux for 18 h and checked with TLC. The
reaction mixture was cooled, diluted with water (200 mL), and
extracted with 3 × 50 mL of DCM. The combined organic extracts
were washed with 50 mL each water and brine, dried with anhydrous
sodium sulfate, and evaporated.
Yield 94% (555 mg, 2.21 mmol), colorless solid, mp 135−138 °C.
TLC 0.40 (LP/EE 30:1). 1H NMR (CDCl3, 200 MHz) δ 6.04 (s, 2H,
O−CH2−O), 7.01 (s, 1H, ArH), 7.06 (s, 1H, ArH), 7.38 (dd, J1 = 8.7
Hz, J2 = 1.9 Hz, 1H, H7), 7.51 (d, J = 8.7 Hz, 1H, H8), 7.79 (d, J = 1.9
Hz, 1H, H5). 13C NMR (CDCl3, 50 MHz) 101.3 (t, O−CH2−O),
103.0 (d), 103.8 (d), 118.1 (s), 127.5 (d), 128.5 (d), 128.9 (d), 131.8
(s), 148.0 (s), 148.3 (s). One signal could not be detected due to low
signal intensity.
(E)-Methyl 3-(Naphtho[2,3-d][1,3]dioxol-6-yl)acrylate (68c). An
8-ml vial with magnetic stirrer, screw cap, and septum was charged
with 68b (300 mg, 1.2 mmol, 1 equiv), methyl acrylate (163 μL, 1.8
mmol, 1.5 equiv), palladium(II) acetate (8 mg, 0.036 mmol, 3 mol %),
and tri-o-tolylphosphine (22 mg, 0.072 mmol, 6 mol %) and ﬂushed
with argon. Triethylamine (0.85 mL) was added via syringe and the
reaction was heated to 80 °C. TLC monitoring (eluent LP/EE 30:1)
showed full conversion after 8 h. The reaction mixture was diluted
with diethyl ether (30 mL). Due to low solubility of the product in
diethyl ether, it was necessary to add ethyl acetate (20 mL) and DCM
(10 mL) to obtain a clear solution. The organic phase was washed with
3 × 10 mL of 0.5 N HCl and 30 mL of brine and dried with sodium
sulfate. Evaporation of the solvent gave the pure product in
quantitative yield.
Yield 100% (310 mg, 1.2 mmol), colorless solid, mp 151−152 °C.
TLC 0.16 (LP/EE 30:1). 1H NMR (CDCl3, 200 MHz) δ 3.81 (s, 3H,
CH3), 6.06 (s, 2H, O−CH2−O), 6.49 (d, J = 16.0 Hz, 1H, H3), 7.10
(s, 1H, ArH), 7.12 (s, 1H, ArH), 7.50 (dd, J1 = 8.6 Hz, J2 = 1.6 Hz, 1H,
H7′), 7.64 (d, J = 8.6 Hz, 1H, H8′), 7.74−7.83 (m, 2H, H2, H5′). 13C
NMR (CDCl3, 50 MHz) δ 51.7 (q, CH3), 101.3 (t, O−CH2−O),
103.9 (d), 104.4 (d), 116.9 (d), 127.6 (d), 128.7 (d), 130.3 (s), 130.4
(s), 131.7 (s), 145.1 (d), 148.2 (s), 148.7 (s), 167.6 (d, COOR). HR-
MS [M + H]+ m/z (pred) = 257.0808, m/z (meas) = 257.0807,
diﬀerence = −0.39 ppm.
Naphtho[2,3-d][1,3]dioxole-5-carboxylic acid (71a). For synthesis
of 71a, a modiﬁcation of a published procedure41 was used. In a two-
necked ﬂask equipped with magnetic stirrer, septum, and balloon,
naphtho[2,3-d][1,3]dioxol-5-yl triﬂuoromethanesulfonate42 (96 mg,
0.3 mmol, 1 equiv), 1,3-bis(diphenylphosphino)propane (dppp; 7 mg,
0.018 mmol, 6 mol %), and palladium(II) acetate (2 mg, 0.009 mmol,
3 mol %) were suspended in DMF/water 3:1 (1 mL). A steel cannula
reaching to the bottom of the ﬂask was used to bubble carbon
monoxide through the solution for 10 min; after that, the balloon was
ﬁlled with CO gas in order to maintain its supply throughout the
reaction time. Hünig’s base (102 μL, 0.6 mmol, 2 equiv) was added via
syringe and the reaction mixture was heated to 70 °C. After 3 h,
reaction control with TLC indicated complete consumption of the
starting material. The reaction mixture was diluted with ethyl acetate
(10 mL) and extracted with 3 × 5 mL of saturated NaHCO3. The
combined aqueous extracts were acidiﬁed to pH = 2 with 2 N HCl and
extracted with 3 × 10 mL of ethyl acetate. The combined organic
extracts were washed with 10 mL each water and brine and dried with
sodium sulfate. Evaporation of the solvent gave the pure product.
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Yield 67% (116 mg, 0.54 mmol), colorless solid, mp 259−263 °C.
TLC 0.60 (CHCl3/MeOH 10%).
1H NMR (acetone-d6, 400 MHz) δ
6.17 (s, 2H, O−CH2−O), 7.33 (s, 1H, ArH), 7.41−7.45 (m, 1H, H7),
8.00 (d, J = 8.0 Hz, 1H, ArH), 8.18 (dd, J1 = 7.4 Hz, J2 = 1.1 Hz, 1H,
ArH), 8.49 (s, 1H, ArH). 13C NMR (acetone-d6, 100 MHz) δ 101.7 (t,
O−CH2−O), 102.2 (d), 104.1 (d), 123.1 (d), 125.7 (s), 128.9 (d),
129.2 (s), 131.6 (s), 132.4 (d), 147.6 (s), 149.5 (s), 168.2 (s, COOH).
Methyl 5,6,7,8-Tetrahydronaphtho[2,3-d][1,3]dioxole-6-carboxy-
late (75a). For synthesis of 75a, a modiﬁcation of a published
method42 was used. A three-necked ﬂask with magnetic stirrer,
septum, reﬂux condenser, and balloon was charged with 5,6-
bis(bromomethyl)benzo[d][1,3]dioxole (2.0 g, 6.5 mmol, 1 equiv),
methyl acrylate (2.94 mL, 32.5 mmol, 5 equiv), and anhydrous DMF
(50 mL) and was ﬂushed with argon. Sodium iodide (3.9 g, 26 mmol,
4 equiv) was added and the reaction was heated to 90 °C overnight (in
previous experiments on a smaller scale, full conversion had been
reached after 2 h). Above 70 °C the reaction mixture began to turn
red. The reaction was quenched with 200 mL of water, and then,
sodium thiosulfate 5% was added until the mixture became colorless.
The aqueous mixture was extracted with 5 × 50 mL of methyl tert-
butyl ether (MTBE). The organic phase was washed with 50 mL each
water and brine, dried with anhydrous sodium sulfate, and evaporated.
Yield 89% (1.35 g, 5.79 mmol), colorless solid, mp 71−72 °C. TLC
0.15 (LP/EE 30:1). 1H NMR (CDCl3, 200 MHz) δ 1.75−1.91 (m,
1H), 2.10−2.22 (m, 1H), 2.61−2.78 (m, 3H), 2.88−2.91 (m, 2H),
3.71 (s, 3H, CH3), 5.87 (s, 2H, O−CH2−O), 6.53 (s, 1H, ArH), 6.55
(s, 1H, ArH). 13C NMR (CDCl3, 50 MHz) δ 25.9 (t, CH2), 28.6 (t,
CH2), 31.6 (t, CH2), 39.9 (d, C6), 51.8 (q, CH3), 100.6 (t, O−CH2−
O), 108.5 (d), 108.6 (d), 127.6 (s), 128.5 (s), 145.7 (s), 145.9 (s),
175.8 (d, COOR)
Methyl Naphtho[2,3-d][1,3]dioxole-6-carboxylate (75b). Com-
pound 75a (100 mg, 0.43 mmol, 1 equiv) was dissolved in benzene (3
mL, p.a.) under argon. DDQ (242 mg, 1.07 mmol, 2.5 equiv) was
added and the reaction mixture was heated to 80 °C for 2 h. TLC
analysis was inconclusive due to very similar Rf values of starting
material and product. Staining with cerium molybdophosphoric acid
dip reagent indicated full conversion (The starting material is readily
stained; the product only weakly). The reaction was quenched with 20
mL of 2 N NaOH and changed color to brown. The reaction was
extracted with 3 × 10 mL of EtOAc. The organic phase was washed
with water until the washings were colorless (5 × 10 mL) and
subsequently washed with brine, dried over sodium sulfate, and
evaporated.
Yield 73% (72 g, 0.31 mmol), colorless solid, mp 130−132 °C,
sublimation above 105 °C. TLC 0.15 (LP/EE 30:1). 1H NMR
(CDCl3, 200 MHz) δ 3.95 (s, 3H, CH3), 6.06 (s, 2H, O−CH2−O),
7.11 (s, 1H, ArH), 7.17 (s, 1H, ArH), 7.66 (d, J = 8.6 Hz, 1H, H8),
7.90 (dd, J1 = 8.6 Hz, J2 = 1.6 Hz, 1H, H7), 8.38 (d, J = 1.6 Hz, 1H,
H5). 13C NMR (CDCl3, 50 MHz) δ 52.1 (q, CH3), 101.4 (t, O−
CH2−O), 103.8 (d), 104.9 (d), 124.1 (d), 125.9 (s), 127.0 (d), 129.6
(s), 129.7 (d), 133.3 (s), 148.2 (s), 149.5 (s), 167.4 (d, COOR). HR-
MS [M + H]+ m/z (pred) = 231.0652, m/z (meas) = 231.658,
diﬀerence = 2.60 ppm.
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